Evidence map›Paper›PMID 40447631›Full record

ArticleScientific reports2025

Allicin induced AMPK signaling attenuated Smad3 pathway mediated lung fibrosis.

Shun Nakazawa, Jia Hou, Motoyasu Kato, Shinsaku Togo, Yuta Arai, Hiroaki Motomura, Koichi Kurata, Takuto Sueyasu, Haruki Hirakawa, Yusuke Ochi and 6 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Altered Metabolism in Idiopathic Pulmonary Fibrosis.Journal of cellular physiology · 2025
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shun Nakazawa *Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Motoyasu Kato, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
Jia Hou *Department of Respiratory and Critical Care Medicine, General Hospital of Ningxia Medical University, Ningxia, China.
Motoyasu KatoDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Motoyasu Kato, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan. mtkatou@juntendo.ac.jp.
Shinsaku TogoDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Motoyasu Kato, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
Yuta AraiDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Motoyasu Kato, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
Hiroaki MotomuraDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Motoyasu Kato, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
Koichi KurataDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Motoyasu Kato, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
Takuto SueyasuDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Motoyasu Kato, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
Haruki HirakawaDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Motoyasu Kato, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
Yusuke OchiDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Motoyasu Kato, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
Issei SumiyoshiDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Motoyasu Kato, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
Junko WatanabeDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Motoyasu Kato, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
Kazuaki HoshiDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Motoyasu Kato, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
Hiroaki IharaDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Motoyasu Kato, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
Kotaro KadoyaDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Motoyasu Kato, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
Kazuhisa TakahashiDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Motoyasu Kato, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allicin, a natural compound derived from garlic, protects against oxidative stress-mediated tissue inflammation and vascular remodeling. Although these are key processes in lung fibrosis, the effects of allicin on this disease have never been evaluated. In this study, we aimed to evaluate the effects of allicin on lung fibroblast-mediated lung fibrosis and its mechanisms. We assessed the effects of allicin on fibronectin-mediated lung fibroblast migration and the contraction of three-dimensional type I collagen gels, and evaluated its anti-fibrotic effects in mice models of bleomycin (BLM)-induced lung fibrosis. The results showed that allicin suppressed transforming growth factor beta 1 (TGFβ1)-stimulated gel contraction and migration, as well as α-smooth muscle actin (α-SMA) and fibronectin. Additionally, allicin upregulated AMP-activated protein kinase (AMPK) phosphorylation, while suppressing Smad3 phosphorylation. An AMPK inhibitor further stimulated TGFβ1-induced gel contraction and migration. Furthermore, allicin suppressed BLM-induced lung fibrosis with suppressed Smad3 phosphorylation and BLM-induced lung injury with suppressed inflammatory cell infiltration in the mouse models. These results suggest that allicin may be a candidate therapeutic agent for suppressing the fibrotic phase mediated by pulmonary fibroblasts through upregulated AMPK resulting in suppressed Smad3 pathway after reducing the acute inflammatory phase.

Indexed as

AMP-Activated Protein KinasesPulmonary FibrosisSignal TransductionSmad3 ProteinSulfinic AcidsActinsAnimalsBleomycinCell MovementDisease Models, AnimalDisulfidesFibroblastsFibronectinsLungMaleMiceActinsallicinAMP-Activated Protein KinasesBleomycinDisulfidesFibronectinsSmad3 ProteinSmad3 protein, mouseSulfinic AcidsTransforming Growth Factor beta1AllicinAMPK inhibitorLung fibrosisTGFβ1/Smad3 pathway

Identifiers

PMID40447631
PMCPMC12125225

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.